Heffter Research Institute

Last updated
Heffter Research Institute
Founded1993
Type 501(c)(3) Nonprofit
Focus Scientific research with psychedelic drugs
Website Heffter Research Institute website

The Heffter Research Institute is a 501(c)(3) nonprofit organization that promotes research with classic hallucinogens and psychedelics, predominantly psilocybin, to contribute to a greater understanding of the mind and to alleviate suffering. Founded in 1993 as a virtual institute, Heffter primarily funds academic and clinical scientists and made more than $3.1 million in grants between 2011 and 2014. [1] [2] [3] [4] Heffter's recent clinical studies have focused on psilocybin-assisted treatment for end-of-life anxiety and depression in cancer patients, as well as alcohol and nicotine addiction.

Contents

History

Arthur Heffter

Arthur Heffter was a German chemist/pharmacologist/physician who first isolated pure Mescaline from the peyote cactus in the late 1890s. He also proved that mescaline was the alkaloid in the cactus that is responsible for its psychoactive properties. This was the first psychedelic compound to be isolated and identified from its natural source, making Dr. Heffter the first scientist to study a pure psychedelic drug. Heffter's elucidation of the mescaline structure allowed it to be prepared by laboratory synthesis in 1919 by Ernst Späth, thus making it available to the wider scientific community.

Founding and history

The institute was founded in 1993 by David E. Nichols. Co-founders included Mark Geyer, Ph.D., Charles Grob, M.D. Dennis McKenna, Ph.D., George Greer, M.D., Phil Wolfson, M.D., and Jerry Patchen. [5]

At the time, psychedelic research had been dormant for approximately 20 years and was not eligible to receive government funding, necessitating private funding to restart the field. [6] The institute was created to secure the private funding and to evaluate research projects for their scientific merit. The institute was incorporated as a nonprofit organization in New Mexico, and received its 501(c)(3) designation from the Internal Revenue Service in 1994. [7]

The first decade of research primarily focused on the mechanisms of action and effects of MDMA, along with clinical studies on ketamine treatment for Heroin addiction in Russia. [8] [9] The institute also funded several small fellowships for young scientists.

Since the turn of the century, the institute's work has focused primarily on psilocybin, including funding the first psychedelic treatment study in the U.S. in decades, treating obsessive-compulsive disorder with psilocybin at the University of Arizona. [10] This study coincided with a number of neuroscience studies of psilocybin and a focus on treating anxiety and depression in cancer patients with psilocybin and addictions.

Organization (board and staff)

The current board of directors consists of seven scientists and five Philanthropists. [11] Dr. Nichols remains the president, with George Greer, M.D. as the medical director and Lynette Herring as the business manager.

Research publications

The institute has provided funding for more than 80 Scientific publications concerned with psychedelic drug research. [12]

Cancer distress

One supported research study found that a single dose of psilocybin significantly reduced anxiety and depressive symptoms in cancer patients. [13] The institute then funded two larger clinical trials of the same treatment at New York University and Johns Hopkins University, which is expected to be published in 2016. [14] Following that, the institute will be supporting an FDA Phase 3 study as a step toward gaining FDA approval of psilocybin for the treatment of anxiety and depression in cancer patients.

Addiction

Five scientific articles on Heffter-supported treatment of addictions with psilocybin have been published. [12] Two recent small pilot studies on alcohol and smoking addiction showed significant positive results. [15] [16] As of early 2016, a large clinical trial is underway at New York University for alcohol dependence and at Johns Hopkins University for smoking.

Two earlier studies on the treatment of heroin addiction with ketamine also showed a significant benefit. [8] [9]

Spirituality

Several Heffter-supported studies on Spiritual experiences and practices involving ayahuasca and psilocybin have been published. [12]

Neuroscience research

There have been more than 70 scientific publications resulting from Heffter-supported neuroscience research, [12] mostly from the Heffter Research Center at the University of Zurich, where one of the board members, Dr. Franz Vollenweider is the principal investigator. [17] One of these studies found that psilocybin inhibits the processing of negative emotions in the brain. [18]

See also

Related Research Articles

<span class="mw-page-title-main">Recreational drug use</span> Use of drugs with the primary intention to alter the state of consciousness

Recreational drug use is the use of one or more psychoactive drugs to induce an altered state of consciousness, either for pleasure or for some other casual purpose or pastime. When a psychoactive drug enters the user's body, it induces an intoxicating effect. Generally, recreational drugs are divided into three categories: depressants, stimulants, and hallucinogens.

<span class="mw-page-title-main">Psilocybin</span> Chemical compound found in some species of mushrooms

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. The most potent are members of genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from about a dozen other genera. Psilocybin is itself biologically inactive but is quickly converted by the body to psilocin, which has mind-altering effects similar, in some aspects, to those of lysergic acid diethylamide (LSD), mescaline, and dimethyltryptamine (DMT). In general, the effects include euphoria, visual and mental hallucinations, changes in perception, distorted sense of time, and perceived spiritual experiences. It can also cause adverse reactions such as nausea and panic attacks.

<span class="mw-page-title-main">Psychopharmacology</span> Study of the effects of psychoactive drugs

Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, behavior, judgment and evaluation, and memory. It is distinguished from neuropsychopharmacology, which emphasizes the correlation between drug-induced changes in the functioning of cells in the nervous system and changes in consciousness and behavior.

<span class="mw-page-title-main">Psychedelic drug</span> Hallucinogenic class of psychoactive drug

Psychedelics are a subclass of hallucinogenic drugs whose primary effect is to trigger non-ordinary mental states and/or an apparent expansion of consciousness. Sometimes, they are called classic hallucinogens, serotonergic hallucinogens, or serotonergic psychedelics, and the term psychedelic is sometimes used more broadly to include various types of hallucinogens or those which are atypical or adjacent to psychedelia such as salvia and MDMA, respectively; this article uses the narrower definition of psychedelics. True psychedelics cause specific psychological, visual, and auditory changes, and oftentimes a substantially altered state of consciousness. Psychedelic states are often compared to meditative, psychodynamic or transcendental types of alterations of the mind. The "classical" psychedelics, the psychedelics with the largest scientific and cultural influence, are mescaline, LSD, psilocybin, and DMT. In particular, LSD has long been considered the paradigmatic psychedelic compound to which all other psychedelics are often or usually compared.

Dissociatives, colloquially dissos, are a subclass of hallucinogens which distort perception of sight and sound and produce feelings of detachment – dissociation – from the environment and/or self. Although many kinds of drugs are capable of such action, dissociatives are unique in that they do so in such a way that they produce hallucinogenic effects, which may include dissociation, a general decrease in sensory experience, hallucinations, dream-like states or anesthesia. Despite most dissociatives’ main mechanism of action being tied to NMDA receptor antagonism, some of these substances, which are nonselective in action and affect the dopamine and/or opioid systems, may be capable of inducing more direct and repeatable euphoria or symptoms which are more akin to the effects of typical “hard drugs” or common drugs of abuse. This is likely why dissociatives are considered to be addictive with a fair to moderate potential for abuse, unlike psychedelics. Despite some dissociatives, such as phencyclidine (PCP) possessing stimulating properties, most dissociatives seem to have a general depressant effect and can produce sedation, respiratory depression, nausea, disorientation, analgesia, anesthesia, ataxia, cognitive and memory impairment as well as amnesia.

<span class="mw-page-title-main">Empathogen–entactogen</span> Class of psychoactive drugs that produce empathic experiences

Empathogens or entactogens are a class of psychoactive drugs that produce experiences of emotional communion, oneness, relatedness, emotional openness—that is, empathy or sympathy—as particularly observed and reported for experiences with 3,4-methylenedioxymethamphetamine (MDMA). This class of drug is distinguished from the classes of hallucinogen or psychedelic, and amphetamine or stimulants. Major members of this class include MDMA, MDA, MDEA, MDOH, MBDB, 5-APB, 5-MAPB, 6-APB, 6-MAPB, methylone, mephedrone, GHB, αMT, and αET, MDAI among others. Most entactogens are phenethylamines and amphetamines, although several, such as αMT and αET, are tryptamines. When referring to MDMA and its counterparts, the term MDxx is often used. Entactogens are sometimes incorrectly referred to as hallucinogens or stimulants, although many entactogens such as ecstasy exhibit psychedelic or stimulant properties as well.

Psychedelic therapy refers to the proposed use of psychedelic drugs, such as psilocybin, MDMA, LSD, and ayahuasca, to treat mental disorders. As of 2021, psychedelic drugs are controlled substances in most countries and psychedelic therapy is not legally available outside clinical trials, with some exceptions.

<span class="mw-page-title-main">Psychonautics</span> Methodology for describing and explaining the subjective effects of altered states of consciousness

Psychonautics refers both to a methodology for describing and explaining the subjective effects of altered states of consciousness, including those induced by meditation or mind-altering substances, and to a research cabal in which the researcher voluntarily immerses themselves into an altered mental state in order to explore the accompanying experiences.

The Multidisciplinary Association for Psychedelic Studies (MAPS) is an American nonprofit organization working to raise awareness and understanding of psychedelic substances. MAPS was founded in 1986 by Rick Doblin and is now based in San Jose, California.

<span class="mw-page-title-main">David E. Nichols</span> American pharmacologist and medicinal chemist

David Earl Nichols is an American pharmacologist and medicinal chemist. Previously the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University, Nichols has worked in the field of psychoactive drugs since 1969. While still a graduate student, he patented the method that is used to make the optical isomers of hallucinogenic amphetamines. His contributions include the synthesis and reporting of escaline, LSZ, 6-APB, 2C-I-NBOMe and other NBOMe variants, and several others, as well as the coining of the term "entactogen".

The Beckley Foundation is a UK-based think tank and UN-accredited NGO, dedicated to activating global drug policy reform and initiating scientific research into psychoactive substances. The foundation is a charitable trust which collaborates with leading scientific and political institutions worldwide to design and develop research and global policy initiatives. It also investigates consciousness and its modulation from a multidisciplinary perspective, working in collaboration with scientists. The foundation is based at Beckley Park near Oxford, United Kingdom. It was founded in 1998, and is directed by Amanda Feilding, Countess of Wemyss.

Amanda Claire Marian Charteris, Countess of Wemyss and March, also known as Amanda Feilding, is an English drug policy reformer, lobbyist, and research coordinator. In 1998, she founded the Foundation to Further Consciousness, later renamed to the Beckley Foundation, a charitable trust which initiates, directs, and supports neuroscientific and clinical research into the effects of psychoactive substances on the brain and cognition. She has also co-authored over 50 papers published in peer-reviewed journals, according to the Foundation. The central aim of her research is to investigate new avenues of treatment for such mental illnesses as depression, anxiety, and addiction, as well as to explore methods of enhancing well-being and creativity.

Hallucinogens are a large and diverse class of psychoactive drugs that can produce altered states of consciousness characterized by major alterations in thought, mood, and perception as well as other changes. Most hallucinogens can be categorized as either being psychedelics, dissociatives, or deliriants.

<span class="mw-page-title-main">Psychoactive drug</span> Chemical substance that alters nervous system function

A psychoactive drug, psychopharmaceutical, psychoactive agent, or psychotropic drug is a chemical substance that changes the function of the nervous system and results in alterations of perception, mood, cognition, and behavior. These substances may be used medically, recreationally, for spiritual reasons, or for research. Some categories of psychoactive drugs may be prescribed by physicians and other healthcare practitioners because of their therapeutic value.

<span class="mw-page-title-main">Harris Isbell</span> American pharmacologist

Harris Isbell was an American pharmacologist and the director of research for the NIMH Addiction Research Center at the Public Health Service Hospital in Lexington, Kentucky from 1945 to 1963. He did extensive research on the physical and psychological effects of various drugs on humans. Early work investigated aspects of physical dependence with opiates and barbiturates, while later work investigated psychedelic drugs, including LSD. The research was extensively reported in academic journals such as the Journal of Pharmacology and Experimental Therapeutics, Psychopharmacologia, and the AMA Archives of Neurology and Psychiatry.

Charles Grob is a professor of Psychiatry & Biobehavioral Sciences and Pediatrics and director of the Division of Child and Adolescent Psychiatry at Harbor–UCLA Medical Center. He received his two BS degrees from Oberlin College and Columbia University, before getting an MD from the State University of New York, Downstate Medical Center. Grob's research interests include anxiety and mood disorders and also self-medication and substance abuse. The FDA approved one of his Phase 1 studies to study the psychological and physiological effects of MDMA and the hallucinogen ayahuasca.

The Spring Grove Experiment is a series of lysergic acid diethylamide (LSD) studies performed from 1963 to 1976 on patients with psychotic illnesses at the Spring Grove Clinic in Catonsville, Maryland. These patients were sponsored by a federal agency called the National Institute of Mental Health to be part of the first study conducted on the effects of psychedelic drugs on people with schizophrenia. The Spring Grove Experiments were adapted to study the effect of LSD and psychotherapy on patients including alcoholics, heroin addicts, neurotics, and terminally-ill cancer patients. The research done was largely conducted by the members of the Research Unit of Spring Grove State Hospital. Significant contributors to the experiments included Walter Pahnke, Albert Kurland, Sanford Unger, Richard Yensen, Stanislav Grof, William Richards, Francesco Di Leo, and Oliver Lee McCabe. Later, Spring Grove was rebuilt into the Maryland Psychiatric Research Center where studies continued to be performed for the advancement of psychiatric research. This study on LSD is the largest study on psychedelic drugs to date.

Entheogenic drugs have been used by various groups for thousands of years. There are numerous historical reports as well as modern, contemporary reports of indigenous groups using entheogens, chemical substances used in a religious, shamanic, or spiritual context.

Psychoplastogens are a group of small molecule drugs that produce rapid and sustained effects on neuronal structure and function, intended to manifest therapeutic benefit after a single administration. Several existing psychoplastogens have been identified and their therapeutic effects demonstrated; several are presently at various stages of development as medications including Ketamine, MDMA, Scopolamine, and the serotonergic psychedelics, including LSD, psilocin, DMT, and 5-MeO-DMT. Compounds of this sort are being explored as therapeutics for a variety of brain disorders including depression, addiction, and PTSD. The ability to rapidly promote neuronal changes via mechanisms of neuroplasticity was recently discovered as the common therapeutic activity and mechanism of action.

Psychedelic treatments for trauma-related disorders are the use of psychedelic substances, either alone or used in conjunction with psychotherapy, to treat trauma-related disorders. Trauma-related disorders, such as post-traumatic stress disorder (PTSD), have a lifetime prevalence of around 8% in the US population. However, even though trauma-related disorders can hinder the everyday life of individuals with them, less than 50% of patients who meet criteria for PTSD diagnosis receive proper treatment. Psychotherapy is an effective treatment for trauma-related disorders. A meta-analysis of treatment outcomes has shown that 67% of patients who completed treatment for PTSD no longer met diagnostic criteria for PTSD. For those seeking evidence-based psychotherapy treatment, it is estimated that 22-24% will drop out of their treatment. In addition to psychotherapy, pharmacotherapy (medication) is an option for treating PTSD; however, research has found that pharmacotherapy is only effective for about 59% of patients. Although both forms of treatment are effective for many patients, high dropout rates of psychotherapy and treatment-resistant forms of PTSD have led to increased research in other possible forms of treatment. One such form is the use of psychedelics.

References

  1. "Guidestar". Guidestar USA. July 7, 2016.
  2. "Guidestar" (PDF). Guidestar. January 2015. Retrieved July 7, 2016.
  3. "Guidestar" (PDF). January 2013. Retrieved July 7, 2016.
  4. "Guidestar" (PDF). January 2012. Retrieved July 7, 2016.
  5. Nichols, David (1994). "The Heffter Research Institute". MAPS Bulletin. IV (4): 34–35. Retrieved 2023-05-13.
  6. Pollan, Michael (February 5, 2015). "New Yorker". The New Yorker.
  7. Nichols, David E. (March 2014). "The Heffter Research Institute: Past and Hopeful Future". Journal of Psychoactive Drugs. 46 (1): 20–26. doi:10.1080/02791072.2014.873688. PMID   24830182. S2CID   21694392.
  8. 1 2 Krupitsky, E (December 2002). "Ketamine heroin 1". J Subst Abuse Treat. 23 (4): 273–83. doi:10.1016/s0740-5472(02)00275-1. PMID   12495789.
  9. 1 2 Krupitsky, EM (March 2007). "Ketamine heroin 2". J Psychoactive Drugs. 39 (1): 13–9. doi:10.1080/02791072.2007.10399860. PMID   17523581. S2CID   41716836.
  10. Moreno, FA (November 2006). "Psilocybin OCD". J Clin Psychiatry. 67 (11): 1735–40. doi:10.4088/jcp.v67n1110. PMID   17196053.
  11. "Heffter Board". Heffter Research Institute. Retrieved July 7, 2016.
  12. 1 2 3 4 "Heffter publications". Heffter Research Institute. Retrieved July 7, 2016.
  13. Grob, Charles S. (January 2011). "HUCLA psilocybin cancer". Archives of General Psychiatry. 68 (1): 71–8. doi:10.1001/archgenpsychiatry.2010.116. PMID   20819978.
  14. Morin, Roc (April 2014). "Atlantic". The Atlantic.
  15. Cortez, Michelle Fay (September 2014). "Bloomberg". Bloomberg News.
  16. Shallow, Parvati (October 2014). "CBS". CBS News.
  17. "Heffter Zürich". University of Zurich. Retrieved July 7, 2016.
  18. "Science Daily". Psilocybin inhibits the processing of negative emotions in the brain. May 2014.